BioNano Genomics, Inc. (BNGO) Posts Net Loss of $7.85M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Bionano Genomics Reports First Quarter 2019 Financial Results and Provides Business Update
May 9, 2019 4:01 PM EDTSAN DIEGO, May 09, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr®, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
Recent Business Highlights
Advanced programs designed to establish Saphyr as the leading platform for cytogenetics laboratories and replace potentially outdated technologies such as fluorescence in-situ hybridization (FISH), karyotyping and microarrays. Bionano is currently conducting two... More